Resistance Rates: Cabenuva vs. Biktarvy vs. Symtuza
Cabenuva (cabotegravir + rilpivirine) has a significantly higher resistance rate of 1-2% even with perfect adherence to scheduled injections, with 2-class resistance emerging in 40-71% of virologic failures—a risk not observed with adherence to oral regimens like Biktarvy or Symtuza 1.
Comparative Resistance Data
Cabenuva (Cabotegravir + Rilpivirine)
- Virologic failure rate: 1-2% despite adherence to scheduled injections 1
- Resistance emergence at failure:
- Clinical trial data: 18 confirmed virologic failures across FLAIR, ATLAS, and ATLAS-2M trials, with treatment-emergent resistance mutations in the majority 2
Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide)
- Virologic failure rate: 0.6-1.4% in treatment-naïve patients 5
- Resistance emergence:
- Identified as the INSTI with lowest VF and lack of resistance mutations in systematic review 5
Symtuza (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide)
- High barrier to resistance due to boosted protease inhibitor component 1
- Recommended for patients with low-level viremia specifically because of resistance barrier 1
- No specific resistance rate data provided in evidence, but boosted darunavir regimens historically have minimal resistance emergence
Critical Clinical Implications
Why Cabenuva Has Higher Resistance Risk
The fundamental problem: Long-acting injectable formulations create prolonged subtherapeutic drug levels during virologic failure, allowing resistance to develop even with perfect injection adherence 1.
Risk factors for Cabenuva failure 1, 2:
- HIV-1 subtype A6 (particularly A1 with L74I polymorphism at baseline)
- BMI >30 kg/m²
- Rilpivirine-associated resistance at baseline (detected by proviral DNA genotyping)
- Baseline integrase L74I polymorphism
Monitoring Recommendations
For Cabenuva patients 1:
- Discuss possibility of treatment failure and 2-class resistance emergence before switching
- Explain potential for viral transmission if rebound occurs
- Counsel on future treatment limitations if resistance develops
- Not recommended if documented or suspected resistance to either cabotegravir or rilpivirine exists
For Biktarvy/dolutegravir-based regimens 1:
- High resistance barrier allows resumption even after treatment interruption
- Patients with NRTI resistance switching to these regimens should be monitored at 1 month, then every 3 months for first year
Evidence Quality Assessment
The 2025 IAS-USA guidelines 1 provide the most authoritative and recent synthesis, clearly stating that "a low (1%-2%) incidence of virologic failure with emergence of 2-class resistance even with adherence to the scheduled injections, a risk not observed with adherence to currently available oral ART" distinguishes Cabenuva from oral regimens.
The systematic review and meta-analysis 3 confirms INSTI resistance prevalence of 61-71% among those with virologic failure on Cabenuva, rates "significantly higher than those for oral INSTI-based regimens."
Real-world French cohort data 4 demonstrates the stark contrast: 3% treatment-emergent RAMs with Biktarvy versus 32% with Cabenuva at virologic failure.
Bottom Line for Clinical Practice
Choose Biktarvy over Cabenuva when resistance risk is a concern. While Cabenuva offers convenience and addresses adherence stigma, it carries unique resistance risks that persist even with perfect adherence. Biktarvy demonstrates superior resistance profile with essentially no resistance emergence in clinical trials and <0.2% in real-world settings 5, 6. Symtuza remains appropriate for specific situations requiring a boosted protease inhibitor, though less commonly used as first-line therapy.